Decrease of AIM2 mediated by luteolin contributes to non-small cell lung cancer treatment.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide.
• Luteolin demonstrates anticancer properties, but its precise mechanism in NSCLC remains unclear.
• The role of Absent in Melanoma 2 (AIM2) inflammasome in NSCLC pathogenesis requires further elucidation.

Purpose of the Study:

• To investigate the underlying mechanism of luteolin's antitumor effects in NSCLC.
• To determine the role of Absent in Melanoma 2 (AIM2) in luteolin's anti-NSCLC activity.
• To explore the potential of targeting AIM2 for NSCLC therapy.

Main Methods:

• Quantitative real-time PCR and Western blotting to assess AIM2 mRNA and protein levels.
• Analysis of cell cycle progression (G2/M phase arrest) and epithelial-mesenchymal transition (EMT) markers.
• In vivo studies using NSCLC xenograft mouse models (A549 and H460 cells).
• AIM2 knockdown and overexpression experiments to validate its role.

Main Results:

• Luteolin significantly downregulated AIM2 expression at both mRNA and protein levels in NSCLC cells.
• Luteolin suppressed AIM2 inflammasome activation, leading to G2/M phase arrest and inhibited EMT.
• AIM2 knockdown abolished luteolin's inhibitory effects, while AIM2 overexpression reversed them.
• Luteolin reduced caspase-1 activation and IL-1β cleavage, confirming AIM2 inflammasome involvement.
• Luteolin's antitumor efficacy was confirmed in vivo, demonstrating an AIM2-dependent mechanism.

Conclusions:

• Luteolin exerts significant antitumor effects against NSCLC through an AIM2-dependent pathway.
• The downregulation of AIM2 is crucial for luteolin's ability to induce cell cycle arrest and inhibit EMT.
• Targeting AIM2 may represent a promising therapeutic strategy for managing NSCLC.